Prognosis
Eli Lilly Says Other Antibody Trials Ongoing After NIH Pause
- Trial paused was using a high-dose version in sicker patients
- Seeking emergency approval for smaller dose in early infection
Photographer: Geert Vanden Wijngaert/Bloomberg
This article is for subscribers only.
Eli Lilly & Co. said it is reviewing safety data that caused federal researchers to pause a trial of the company’s Covid-19 antibody in hospitalized patients. In the meantime, other trials using lower doses of the drug outside the hospital will continue.
On Tuesday, Lilly said enrollment had been paused in the ACTIV-3 trial of its monoclonal antibody treatment sponsored by the National Institutes of Health. The trial is testing a high-dose version of the treatment combined with the drug remdesivir, considered to be a standard of care. To date, the study has enrolled 326 participants who are hospitalized with Covid-19.